NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of Ascendis Pharma shareholders ASND following allegations that Ascendis has disclosed potentially materially misleading business information to the investing public.

SO WHAT: If you have purchased Ascendis securities, you may be entitled to compensation without payment of expenses or costs through a contingency fee arrangement. Law firm Rosen is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To participate in the prospective class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=13973 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email pkim@rosenlegal.com or cases@rosenlegal.com for information about the Class Action.

WHAT IS THIS ABOUT: On April 3, 2023, prior to the market close, Ascendis announced that the US Food & Drug Administration (“FDA”) had notified the Company that the FDA had identified deficiencies in the Company’s regulatory submission (“NDA”) as part of its ongoing review. for TransCon PTH (palopegteriparatide) in hypoparathyroidism, which prevents them from having further discussions on labeling and post-marketing requirements/commitments at this time. The deficiencies were not disclosed in the letter.”

As a result of this news, the price of Ascendis’ American Depository Shares (“ADSs”) fell as low as $64.33 on April 3, 2023, a 40% decrease from the closing price on April 2, 2023.

WHY ROSES LAW: We encourage investors to select qualified advisors with a track record in leadership positions. Frequently, companies that issue notices do not have comparable experience, resources, or meaningful recognition from peers. Many of these firms do not conduct securities class action lawsuits. Be wise in choosing a lawyer. The Rosen law firm represents investors around the world and focuses its practice on securities class actions and shareholder derivatives…